Result of AGM and Completion of Acquisition

AI SummaryClose X

Thalia Therapeutics plc announced the successful completion of its acquisition of Sanmirna Therapeutics Inc. following shareholder approval at its Annual General Meeting. The company issued 485,107,215 new ordinary shares as initial consideration, along with a £764,357 Convertible Loan Note. Thalia also conditionally raised £2.75 million through the placing and subscription of 458,333,333 new ordinary shares. Following these transactions and the admission of new shares, expected on July 20, 2026, the company's enlarged issued share capital will comprise 1,775,720,897 ordinary shares. All resolutions at the AGM, including director re-elections and the approval of the acquisition, passed with significant shareholder support.

Disclaimer*

UK 100

Latest directors dealings